169045-04-9

Usage

Uses

Used in Scientific Research:
2-Amino-5-bromo-4-methoxybenzoic acid is used as a chemical compound for various scientific research applications in laboratories. Its unique structure and functional groups make it a valuable candidate for studies in organic chemistry, medicinal chemistry, and material science. 2-Amino-5-bromo-4-methoxybenzoic acid's properties, such as its reactivity and stability, can be explored for potential applications in the development of new drugs, materials, or chemical processes.

Upstream product

• 871878-59-0 acetic acid-(4-bromo-5-methoxy-2-methyl-anilide) 
• 4294-95-5 4-methoxyanthranilic acid 
• 50868-75-2 5’-methoxy-2’-methylacetanilide 
• 861298-97-7 2-acetylamino-5-bromo-4-methoxy-benzoic acid 

Downstream Products

• 950577-05-6 6-bromo-7-methoxyquinazoline-4(3H)-one 
• 1256955-27-7 6-bromo-4-chloro-7-methoxyquinazoline 
• 169044-96-6 methyl 2-amino-5-bromo-4-methoxybenzoate 
• 861298-96-6 5-bromo-2-carboxymethylsulfanyl-4-methoxy-benzoic acid 

Relevant academic research and scientific papers

Compound used as kinase inhibitor, and application thereof

The invention relates to a compound used as a kinase inhibitor, and application thereof. The structure of the compound is shown as a formula I in the specification. The compound used as the kinase inhibitor provided by the invention has good inhibitory activity on EGFR and Her2 exon 20 insertion mutation, and has great potential to be developed into drugs for treating related diseases.

Imidazo[1,5-a]quinazoline-5(4H)-ketone derivative as well as preparation method and application thereof

The invention relates to an imidazo[1,5-a]quinazoline-5(4H)-ketone derivative as well as a preparation method and application thereof. The imidazo[1,5-a]quinazoline-5(4H)-ketone derivative disclosed by the invention can be used for preparing a BET protein

QUINAZOLINONE COMPOUNDS

New quinazolinone compounds are disclosed, as well as pharmaceutical compositions containing quinazolinones and methods for the treatment of diseases and conditions associated with mitochondrial dysfunction.

DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY

Provided herein are compounds of the Formula (I), (II), and (III), as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.

QUINAZOLINE COMPOUND FOR EGFR INHIBITION

Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

QUINAZOLINE-BASED KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS

The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; 5 (IA) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof

Substituted 4-amino-quinazoline compounds corresponding to formula I methods for their production, pharmaceutical compositions containing these compounds as active agents, and the uses thereof for treating or inhibiting disorders or disease states.